Literature DB >> 12142098

Patients with brain metastases: hope for recursive partitioning analysis (RPA) class 3.

Johannes Lutterbach1, Susanne Bartelt, Ella Stancu, Roland Guttenberger.   

Abstract

PURPOSE: The objectives of the present study were (a) to validate the prognostic classification derived from recursive partitioning analysis (RPA) of the Radiation Therapy Oncology Group (RTOG); (b) to identify prognostic factors in class 3; (c) to examine the impact of treatment related variables on the prognosis in class 3. PATIENTS AND METHODS: Nine hundred and sixteen patients with brain metastases had resection and whole brain radiotherapy (WBRT, n = 257) or WBRT alone (n = 659) at our institution from 1985 to 2000. Patients were grouped into RPA classes 1, 2, and 3 (n = 67, 441, and 408, respectively).
RESULTS: Median survival of the whole group was 3.4 months. Median survival in classes 1, 2, and 3 was 8.2, 4.9, and 1.8 months, respectively. In class 3, age (<65 years vs. > or =65 years, relative risk (RR) 0.75), status of the primary tumor (controlled vs. uncontrolled, RR 0.86), and the number of brain metastases (single vs. multiple, RR 0.76) were independent prognostic variables. We defined three prognostic subgroups: class 3a (n = 51): age <65 years, controlled primary tumor, single brain metastasis; class 3c (n = 44): age > or =65 years, uncontrolled primary tumor, multiple brain metastases; class 3b (n = 313): all other patients. Median survival in classes 3a, 3b, and 3c was 3.2, 1.9, and 1.2 months, respectively (P < 0.0001). Intra-class comparisons showed that resection followed by WBRT yielded significantly better survival compared with WBRT alone.
CONCLUSION: Our results validate the RTOG RPA classification for patients with brain metastases. The variables age, status of the primary, and number of brain metastases allow the division of class 3 into prognostic subgroups. Even class 3 patients may benefit from more aggressive treatment strategies. Copyright 2002 Elsevier Science Ireland Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 12142098     DOI: 10.1016/s0167-8140(02)00119-6

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  12 in total

Review 1.  Optimal management of brain metastases from breast cancer. Issues and considerations.

Authors:  Rupert Bartsch; Anna S Berghoff; Matthias Preusser
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

2.  The impact of tumour histology and recursive partitioning analysis classification on the prognosis of patients treated with whole-brain hypofractionated radiotherapy for brain metastases: analysis of 382 patients.

Authors:  M Buglione; L Bandera; S Grisanti; N Pasinetti; P Borghetti; F Barbera; L Triggiani; L Costa; B Shehi; B Bonetti; S Magrini
Journal:  Radiol Med       Date:  2011-10-21       Impact factor: 3.469

3.  Poor performance status and brain metastases treatment: who may benefit from the stereotactic radiotherapy?

Authors:  Katarzyna Holub; Guillaume Louvel
Journal:  J Neurooncol       Date:  2021-02-15       Impact factor: 4.130

4.  Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.

Authors:  Rupert Bartsch; Andrea Rottenfusser; Catharina Wenzel; Karin Dieckmann; Ursula Pluschnig; Gabriela Altorjai; Margaretha Rudas; Robert M Mader; Richard Poetter; Christoph C Zielinski; Guenther G Steger
Journal:  J Neurooncol       Date:  2007-06-08       Impact factor: 4.130

5.  Stereotactic radiosurgery in elderly patients with brain metastases.

Authors:  Giuseppe Minniti; Vincenzo Esposito; Enrico Clarke; Claudia Scaringi; Alessandro Bozzao; Gaetano Lanzetta; Vitaliana De Sanctis; Maurizio Valeriani; Mattia Osti; Riccardo Maurizi Enrici
Journal:  J Neurooncol       Date:  2012-11-28       Impact factor: 4.130

6.  Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases.

Authors:  R Bartsch; A Berghoff; U Pluschnig; Z Bago-Horvath; P Dubsky; A Rottenfusser; C DeVries; M Rudas; F Fitzal; K Dieckmann; R M Mader; M Gnant; C C Zielinski; G G Steger
Journal:  Br J Cancer       Date:  2011-11-29       Impact factor: 7.640

Review 7.  Radiation therapy for older patients with brain tumors.

Authors:  Giuseppe Minniti; Andrea Riccardo Filippi; Mattia Falchetto Osti; Umberto Ricardi
Journal:  Radiat Oncol       Date:  2017-06-19       Impact factor: 3.481

8.  Presentation and outcome in cancer patients with extensive spread to the brain.

Authors:  Carsten Nieder; Adam Pawiniski; Astrid Dalhaug
Journal:  BMC Res Notes       Date:  2009-12-12

Review 9.  Prognostic indices for brain metastases--usefulness and challenges.

Authors:  Carsten Nieder; Minesh P Mehta
Journal:  Radiat Oncol       Date:  2009-03-04       Impact factor: 3.481

10.  Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.

Authors:  Paula Mulvenna; Matthew Nankivell; Rachael Barton; Corinne Faivre-Finn; Paula Wilson; Elaine McColl; Barbara Moore; Iona Brisbane; David Ardron; Tanya Holt; Sally Morgan; Caroline Lee; Kathryn Waite; Neil Bayman; Cheryl Pugh; Benjamin Sydes; Richard Stephens; Mahesh K Parmar; Ruth E Langley
Journal:  Lancet       Date:  2016-09-04       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.